Access PrevIOTOX Testing
PrevIOTOX TESTING ACCESS
To help cancer patients avoid side effects from immunotherapy
While immunotherapy has been a breakthrough in cancer treatment, it can also cause the immune system to attack healthy cells. So patients often experience side effects from immunotherapy called immune-related adverse events (irAEs).
The germline genetic variants we study can help predict a patient's risk of these side effects from immune therapy.
PrevIOTOX is a genetic test that can predict an up to a 9-fold increased risk of these side effects from treatment with anti-PD1 or anti-PDL1 immunotherapies.
PrevIOTOX Testing
Testing performed by MiraDX, patient access through MiraKind.
You are eligible to order PrevIOTOX testing through MiraKind if all of the following apply to you:
- You have a cancer diagnosis
- You are considering anti-PD1 or anti-PDL1 treatment
- You agree to participate in a MiraKind research registry
$500*
*Cost of testing through MiraKind only. If you need further financial assistance, apply here.
Questions? Read our PrevIOTOX FAQ or Contact us
Frequently asked questions about MiraDX PrevIOTOX testing through MiraKind
General questions about PrevIOTOX
Accessing PrevIOTOX through MiraKind
Taking the test
Participating in our research registry
Disclosure: Any discussion of medical management options is for general informational purposes only and does not constitute a medical recommendation. All medical management decisions should be made based on consultation between each patient and his or her healthcare professional.
References
- Yuan Y, Weidhaas JB. Functional microRNA binding site variants. Mol Oncol. 2019;13(1):4-8. doi:10.1002/1878-0261.12421.
- Weidhaas JB. Identifying MicroRNA Pathway Variants as Biomarkers of Patient Selection for Immune Therapy. Methods Mol Biol. 2020;2055:203-212. doi:10.1007/978-1-4939-9773-2_9.
- Weidhaas J, Marco N, Scheffler AW, et al. Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy. Journal for ImmunoTherapy of Cancer. 2022;10(2):e003625. doi:10.1136/jitc-2021-003625.
